About Kriya Therapeutics
Kriya Therapeutics is a company based in Redwood City (United States) founded in 2012 by Shankar Ramaswamy, Roger Jeffs, and Fraser Wright.. Kriya Therapeutics has raised $930.93 million across 5 funding rounds from investors including Amplo, Patient Square Capital and Bluebird Ventures. The company has 159 employees as of December 31, 2023. Kriya Therapeutics has completed 2 acquisitions, including Redpin Therapeutics and Tramontane Therapeutics. Kriya Therapeutics offers products and services including AAV-FGF21 Gene Therapy, KRIYA-586, and Gene Therapy Platform. Kriya Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others.
- Headquarter Redwood City, United States
- Employees 159 as on 31 Dec, 2023
- Founders Shankar Ramaswamy, Roger Jeffs, Fraser Wright
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kriya Therapeutics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$930.93 M (USD)
in 5 rounds
-
Latest Funding Round
$313.3 M (USD), Series C
Jul 31, 2025
-
Investors
Amplo
& 14 more
-
Employee Count
159
as on Dec 31, 2023
-
Investments & Acquisitions
Redpin Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kriya Therapeutics
Kriya Therapeutics offers a comprehensive portfolio of products and services, including AAV-FGF21 Gene Therapy, KRIYA-586, and Gene Therapy Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats liver fibrosis by reversing damage through gene-based intervention.
Targets thyroid eye disease with preclinical therapeutic approaches.
Supports development of therapies for diabetes and epilepsy via innovation.
Unlock access to complete
Unlock access to complete
Funding Insights of Kriya Therapeutics
Kriya Therapeutics has successfully raised a total of $930.93M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $313.3 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $313.3M
- First Round First Round
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series C - Kriya Therapeutics | Valuation |
investors |
|
| May, 2022 | Amount | Series C - Kriya Therapeutics | Valuation | Patient Square Capital | |
| Jun, 2021 | Amount | Series B - Kriya Therapeutics | Valuation | Patient Square Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kriya Therapeutics
Kriya Therapeutics has secured backing from 15 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Amplo, Patient Square Capital and Bluebird Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Patient Square Capital is focused on health care investments.
|
Founded Year | Domain | Location | |
|
Bluebird Ventures is engaged in life sciences venture capital investment.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kriya Therapeutics
Kriya Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Redpin Therapeutics and Tramontane Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapies for neurological and metabolic disorders are developed.
|
2021 | ||||
|
Cell therapies for neurological and psychiatric disorders are developed.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Kriya Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kriya Therapeutics Comparisons
Competitors of Kriya Therapeutics
Kriya Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Biogen and Alnylam, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kriya Therapeutics
Frequently Asked Questions about Kriya Therapeutics
When was Kriya Therapeutics founded?
Kriya Therapeutics was founded in 2012 and raised its 1st funding round 7 years after it was founded.
Where is Kriya Therapeutics located?
Kriya Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Who is the current CEO of Kriya Therapeutics?
Shankar Ramaswamy is the current CEO of Kriya Therapeutics. They have also founded this company.
Is Kriya Therapeutics a funded company?
Kriya Therapeutics is a funded company, having raised a total of $930.93M across 5 funding rounds to date. The company's 1st funding round was a Series B of $100M, raised on Jun 01, 2019.
How many employees does Kriya Therapeutics have?
As of Dec 31, 2023, the latest employee count at Kriya Therapeutics is 159.
What does Kriya Therapeutics do?
Kriya Therapeutics was founded in 2012 in Redwood City, United States, and operates in the biotechnology sector focused on diabetes treatments. Gene therapies using adeno-associated virus (AAV) vectors are developed for type 1 and type 2 diabetes. Key candidates include KT-A112, which incorporates insulin and glucokinase proteins; KT-A522, a glucagon-like peptide-1 receptor agonist; and KT-A832, an insulin growth factor formulation. Operations center on advancing these therapies toward clinical applications.
Who are the top competitors of Kriya Therapeutics?
Kriya Therapeutics's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
What products or services does Kriya Therapeutics offer?
Kriya Therapeutics offers AAV-FGF21 Gene Therapy, KRIYA-586, and Gene Therapy Platform.
How many acquisitions has Kriya Therapeutics made?
Kriya Therapeutics has made 2 acquisitions, including Redpin Therapeutics, and Tramontane Therapeutics.
Who are Kriya Therapeutics's investors?
Kriya Therapeutics has 15 investors. Key investors include Amplo, Patient Square Capital, Bluebird Ventures, CAM Capital, and Dexcel Pharma.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.